FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL							
	OMB Number:	3235-0287						
	Estimated average burden							
- 1	hours por rosponso:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

				-												
Name and Address of Reporting Person* <u>Clemens Kevan</u>				2. Issuer Name and Ticker or Trading Symbol MEI Pharma, Inc. [MEIP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(F I PHARMA		(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/01/2021							Officer (give title Other (specify below) below)				
11455 El	L CAMINO	REAL, SUITE	250	4.	If Ame	endment,	Date	of Original File	ed (Month/Da	ay/Year)	6.	Individual or Joint/Group Filing (Check Applic				
(Street)	EGO C.	A	92130								Lir	Line) X Form filed by One Reporting Persor Form filed by More than One Report Person				I
(City)	(S	itate)	(Zip)													
		Tab	le I - Non-Dei	rivativ	e Se	curities	s Ac	quired, Di	sposed o	f, or Ber	neficia	lly Owned	l			
Date		Date	nsaction	action 2A. Deemed Execution Date if any (Month/Day/Yea		Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)					Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	ion(s) and 4)			(
			Table II - Deriv (e.g.,					uired, Dis s, options,				y Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		5. Numl of Derivati Securiti Acquire (A) or Dispose of (D) (I 3, 4 and	ive ies ed ed nstr.	6. Date Exerc Expiration Da (Month/Day/)	ite	7. Title and of Securiti Underlying Derivative (Instr. 3 an	es J Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$2.95	07/01/2021		A		50,000		(1)	07/01/2031	Common Stock	50,000	\$0.00	50,00	0	D	
Stock Option (Right to Buy)	\$6.47							(2)	12/03/2024	Common Stock	12,667	,	12,66	7	D	
Stock Option (Right to Buy)	\$1.57							(2)	07/28/2025	Common Stock	20,000		20,000		D	
Stock Option (Right to Buy)	\$1.36							(2)	07/29/2026	Common Stock	40,000		40,00	0	D	
Stock Option (Right to Buy)	\$2.83							(2)	07/06/2027	Common Stock	40,000		40,00	0	D	
Stock Option (Right to Buy)	\$4.28							(2)	07/12/2028	Common Stock	40,000		40,00	0	D	
Stock Option (Right to Buy)	\$2.52							(2)	07/01/2029	Common Stock	40,000		40,00	0	D	
Stock Option (Right to Buy)	\$3.49							(2)	07/02/2030	Common Stock	50,000		50,00	0	D	

Explanation of Responses:

- 1. The options will vest in equal monthly installments over twelve months.
- 2. All of such options are presently exercisable.

Remarks:

/s/ Brian G. Drazba, as attorney

07/06/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.